Arcutis Biotherapeutics rilis transkrip paparan kinerja kuartal II 2026

Reuters2026/08/11 20:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Arcutis Biotherapeutics memaparkan hasil kinerja kuartal II 2026 pada earnings call 5 Agustus 2026, dihadiri CEO Frank Watanabe, CMO Patrick Burnett, CFO Latha Vairavan, IR Brian Schoelkopf.
Net product revenue ZORYVE 129,9 juta pada kuartal II, naik 59% (yoy) serta naik 23% (qoq); resep kuartalan tembus 280.000.
Proyeksi penjualan bersih 2026 dinaikkan menjadi 525 juta-540 juta dari 480 juta-495 juta; pertumbuhan terutama didorong permintaan.
Laba bersih 15 juta berbalik dari rugi bersih 15,9 juta; arus kas operasi 12,6 juta, kas dan sekuritas 238,9 juta, utang 101,9 juta.
FDA menyetujui ZORYVE cream 0,3% untuk psoriasis plak usia 2 tahun ke atas; sNDA 0,05% untuk dermatitis atopik bayi 3 bulan diterima, PDUFA 23 Februari 2027.
Inisiatif akses pasien diluncurkan: platform telehealth dermatologi dengan pengiriman rumah melalui pharmacy hub, biaya pasien mengikuti cakupan asuransi.
Kemitraan platform alur kerja resep berbasis AI ditujukan mempercepat prior authorization, asesmen biaya, serta rute pemenuhan di praktik dermatologi.
Uji fase II vitiligo selesai rekrutmen; pembacaan data serta keputusan lanjut ditargetkan kuartal IV 2026, HS dibaca kuartal I 2027.
Arcutis memulai studi pruritus INTEGUMENT-ITCH, studi psoriasis kuku, serta studi efek kulit pada pasien kanker pengguna PD-1/PD-L1 untuk publikasi data.
Chief Commercial Officer Todd Edwards mundur efektif akhir bulan; Rob Lisicki ditunjuk sebagai interim CCO saat pencarian nasional berlangsung.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arcutis Biotherapeutics rilis transkrip paparan kinerja kuartal II 2026

You may also like

Crypto prices